AbbVie
ABBV
#25
Rank
NZ$696.20 B
Marketcap
NZ$393.92
Share price
1.80%
Change (1 day)
30.29%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2025 (TTM): NZ$2.32

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$2.35. In 2024 the company made an earnings per share (EPS) of NZ$4.21 a decrease over its 2023 EPS that were of NZ$4.77.

EPS history for AbbVie from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$2.32-44.96%
2024NZ$4.21-11.86%
2023NZ$4.77-58.95%
2022NZ$11.632.49%
2021NZ$11.34121.58%
2020NZ$5.12-44.7%
2019NZ$9.2645.84%
2018NZ$6.359.72%
2017NZ$5.79-9.54%
2016NZ$6.4016.28%
2015NZ$5.50184.1%
2014NZ$1.94-57.15%
2013NZ$4.52

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.99 27.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$5.16 119.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$35.63 1,417.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$22.63 863.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$11.32 382.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$19.09 712.95%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$6.25 166.00%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$5.27 124.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$7.49 218.82%๐Ÿ‡บ๐Ÿ‡ธ USA